echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The cro industry, which is listed one by one and R & D booster, has entered the new normal of M & A integration

    The cro industry, which is listed one by one and R & D booster, has entered the new normal of M & A integration

    • Last Update: 2017-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: on June 13, 2017, Yaoming Biotechnology Co., Ltd., a affiliated company of YaoMing Kant, was officially listed on the stock exchange of Hong Kong As the second largest board of Wuxi Pharmaceutical Co., Ltd., the largest biological agent R & D service provider in China, the news of the listing of Wuxi Pharmaceutical Co., Ltd once again aroused hot debate in the domestic pharmaceutical industry and cro circle However, in the evening of the previous day, quantum high tech, which had been suspended for nearly half a year, issued a plan for major asset restructuring It was proposed to issue shares and pay cash to purchase 100% of the equity of cro Shanghai wisdom Chemical Research Co., Ltd with a total price of 2.380 billion yuan One is listed, one is acquired The frequent action of cro industry promotes the nerve of pharmaceutical industry CrO (contract research organization) refers to the professional organization that provides clinical or preclinical research services of new drugs to pharmaceutical enterprises in the form of contract, undertakes the task of research and development of some new drugs and application for registration, mainly serving the new drugs on the market and before the stage The emergence of cro companies in the cro industry is driven by many factors, and the traceability is the result of the division of labor in the global pharmaceutical R & D system From the long-term development trend of this industry, cro companies aiming to improve efficiency and reduce costs have a good development prospect driven by industrial policies and the rising cost of new drug research and development Especially in recent decades, due to the increasing cost of basic test and increasingly strict supervision, the cost of new drug research and development has increased rapidly, which brings huge research and development pressure to pharmaceutical enterprises The investment of pharmaceutical enterprises in the field of new drug research and development is increasing year by year, which further promotes the demand of cro enterprises to expand gradually (average R & D cost of new drugs in recent years) from the perspective of short-term development trend, affected by profit loss brought by global patent cliff and domestic drug consistency evaluation, pharmaceutical enterprises are facing fierce competition of generic drugs If there are not enough new products on the market to ease, the turnover and profit obtained by patent protection in the past will plummet According to evaluate Phama, the patent cliff will cause $79 billion in sales losses of global pharmaceutical companies in 2016-2020 To solve this problem, cro company can help pharmaceutical companies to accelerate their progress in the limited patent period, so that new drugs can be listed and sold as soon as possible to achieve returns Three levels of domestic cro Market While the cro market is booming due to various reasons such as policies and industries, its cooperation mode with pharmaceutical enterprises has gradually changed from the traditional mode of "single outsourcing" to the innovative mode and result oriented mode Some early developing cro enterprises, such as Kuntai, yaomingkant, etc., have even formed their own risk sharing mode to participate in new drugs more deeply Among the R & D projects, "domestic cro industry is ready to develop, and consistency evaluation may help What do you know about these companies?"? 》Such enterprises as Wuxi Pharmaceutical Co., Ltd are no longer pure cro enterprises, but have evolved into drug companies that integrate drug discovery, research, market and overall layout (domestic cro market competition pattern) the current domestic cro market process is divided into three levels The first stage is the branches of large cro enterprises in China, with strong R & D strength and strong capital strength, which can carry out international multi center experiments The second stage is the large-scale local cro enterprises represented by Wuxi apptec, tiger pharmaceutical, Boji pharmaceutical, etc they are familiar with the domestic market and can provide most of the pre clinical and clinical trial research services, but there is still a gap with the first-stage multinational cro enterprises in terms of capital strength, business scale and international multi-center trial development However, these enterprises have attracted high-end talents, launched cross-border M & A and expanded the scale of international business The third level is the small and medium-sized local cro enterprises with the largest number and the lowest access threshold Most of them mainly provide low-tech intensive work such as registration and declaration, and their profitability is poor Of course, if the operation is standardized, these enterprises will survive and grow in the fierce competition In the period of market integration, the cro industry is also responding to the requirements of the globalization of pharmaceutical research and development and the scale of multi-national and multi center clinical trials The importance of cro industry in the pharmaceutical industry is increasingly prominent, so that more and more pharmaceutical enterprises have the intention to acquire it The reorganization and merger of the industry also brings unparalleled development opportunities for the domestic cro industry Based on the analysis of quantum high tech's acquisition of wisdom chemical, quantum high tech, which has been focusing on the big health industry, has long been committed to the research, development, production and sales of probiotic series products represented by fructooligosaccharide and galactooligosaccharide If the acquisition of Shanghai wisdom Chemical Research Co., Ltd., a cro enterprise, is completed, it will expand the business of the company to cro and CMO Field In addition, in mid May this year, Wuxi apptec also announced the acquisition of Shanghai Huiyuan Biotechnology Co., Ltd This cro company mainly provides a series of preclinical drug R & D services, such as drug target validation, active compound identification, lead compound discovery, in vivo pharmacology research, etc., and its customer base includes all ten pharmaceutical companies in the world The acquisition is helpful for Wuxi apptec to further improve and expand its integrated R & D service platform In fact, since 2011, the M & A of cro industry has been continuous In China alone, there have been wise chemical M & A of Charles River Shanghai laboratory, to absorb foreign R & D models and provide new preclinical drug R & D services; Wuxi Pharmaceutical Co., Ltd and AstraZeneca, PRA, Juno joint venture, invest in innovative biological drug R & D, cell therapy, improve cro service capacity, and acquire NextCode, crelux, and develop gene biotechnology; Tiger Pharmaceutical Co., Ltd acquires BDM of the United States, Fangda pharmaceutical, Renzhi of Beiyi, dreamcis of South Korea, and jiejie Tongtairui, expand cro business layout; Fangen pharmaceutical completes the complete merger and acquisition of imedglobal through its overseas branch fmdk & L; Boji pharmaceutical plans to acquire Humphries pharmaceutical consulting to expand North American business It can be seen that local cro enterprises with strong capital and technological strength are gradually demonstrating extraordinary resource integration ability in the international market by using international resources and international market to strengthen their own strength We will summarize the M & A integration cases in cro field in recent years into the following table for readers.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.